spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  gene therapeutics 

 HSMN NewsFeed - 19 Jan 2026
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to iRegene's NouvNeu001, Making It the World's First iPSC Therapy with Both FTD and RMAT Recognitions
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 13 Oct 2021
Poseida Therapeutics Announces Leadership Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Aug 2021
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Mar 2021
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jun 2020
Poseida Therapeutics Raises $110 Million in Series D Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 24 Mar 2020
MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T(TM)) Therapies
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 20 Dec 2019
Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 17 Sep 2019
AskBio Acquires Assets from RoverMed BioSciences, Adds Nanotechnology Precision to Delivery of AAV Gene Therapeutics
Biopharmaceuticals Drug Delivery Acquisitions
 HSMN NewsFeed - 25 Feb 2019
Gracell Biotechnologies Completes $85 Million Series B for Immune Cell Gene Therapies
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Dec 2018
GenEdit Closes $8.5 million Series Seed Financing
Regenerative Medicine Venture Capital Personnel
 HSMN NewsFeed - 2 Nov 2010
Unigene Names Alex Martin VP Business Development and Head of Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Sep 2008
ARIAD Announces Court Rulings Regarding NF-(kappa)B Patent Lawsuit with Amgen
Biopharmaceuticals Litigation
 HSMN NewsFeed - 12 Sep 2008
ARIAD Announces Merger with ARIAD Gene Therapeutics, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 May 2008
ARIAD Appoints Former Bristol-Myers Squibb Executive to Lead Corporate Legal and Compliance Functions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Feb 2008
ARIAD Appoints Richard W. Pascoe as Chief Operating Officer and Expands Role of Timothy P. Clackson, Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Feb 2008
Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Nov 2007
ARIAD Expands Leadership Team with Three New Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Oct 2007
ARIAD Announces Collaboration with ICON Medical to Develop and Commercialize Novel Deforolimus-Eluting Stents
Devices Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 2 Oct 2007
ARIAD Names Vice President, Clinical Operations to Further Enhance Global Clinical Development Efforts
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Sep 2007
ARIAD Initiates Phase 3 'Succeed' Trial of Oral Deforolimus in Patients with Metastatic Sarcomas
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2007
ARIAD Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Oral Deforolimus
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Aug 2007
Deforolimus Approved as Nonproprietary Name for AP23573 - ARIAD's Novel mTOR Inhibitor
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jul 2007
ARIAD and Merck & Co., Inc. Announce Global Collaboration to Jointly Develop and Commercialize AP23573 - ARIAD's Novel mTOR Inhibitor - for Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2007
ARIAD Announces Appointment of Senior Oncology Executive to Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2007
ARIAD Presents Additional Efficacy Data on AP23573, Novel mTOR Inhibitor, in Phase 2 Advanced Sarcoma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 May 2007
Quest Group International, Inc. Raises $20 Million, Acquires Extensive New Generation Oncology Portfolio and Announces Three Lead Therapeutic Product Programs
Biopharmacetuicals Oncology Licensing
 HSMN NewsFeed - 14 Apr 2007
ARIAD files claim against Amgen and Wyeth Alleging Infringement of NF-(kappa)B Patent by Enbrel(R) and Kineret(R)
Biopharmaceuticals Litigation
 HSMN NewsFeed - 12 Feb 2007
ARIAD Grants Second Commercial License to Its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 2 Nov 2006
ARIAD Presents Expanded Efficacy Data On AP23573, Novel mTOR Inhibitor, In Phase 2 Advanced Sarcoma Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Oct 2006
Kosan Appoints Robert De Jager as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
Return to NewsFeed  

 Additional items found! 11

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 11 additional stories matching:
gene therapeutics
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!